Heart failure and chronic obstructive pulmonary disease: The quandary of beta-blockers and beta-agonists

Journal of the American College of Cardiology

Volumn 57, Issue 21, 2011, Pages 2127-2138

  Hawkins, Nathaniel M ^a   Petrie, Mark C ^b   MacDonald, Michael R ^b   Jhund, Pardeep S ^c   Fabbri, Leonardo M ^d   Wikstrand, John ^e   McMurray, John J V ^c  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

adrenergic beta antagonists; chronic obstructive pulmonary disease; heart failure

Indexed keywords

ACEBUTOLOL; ATENOLOL; BAMBUTEROL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; DIGOXIN; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; NEDOCROMIL; OXPRENOLOL; PINDOLOL; PIRBUTEROL; PLACEBO; PRACTOLOL; PRENALTEROL; PROPRANOLOL; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE; XAMOTEROL;

ARTICLE; ASTHMA; BRONCHITIS; BRONCHOSPASM; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DYSPNEA; HEART FAILURE; HUMAN; LIPID SOLUBILITY; LOW DRUG DOSE; LUNG FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SINGLE DRUG DOSE; DRUG CONTRAINDICATION; REVIEW;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79956116545     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.02.020     Document Type: Review

References (111)

1. K. Dickstein, A. Cohen-Solal, and G. Filippatos ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology Eur Heart J 29 2008 2388 2442
2. GOLD Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Workshop Report Updated 2008 http://www.goldcopd. com Accessed October 2010
3. U. Poller, B. Fuchs, and A. Gorf Terbutaline-induced desensitization of human cardiac beta 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen Cardiovasc Res 40 1998 211 222 (Pubitemid 28435446)
4. N.M. Hawkins, M.C. Petrie, P.S. Jhund, G.W. Chalmers, F.G. Dunn, and J.J. McMurray Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology Eur J Heart Fail 11 2009 130 139
5. G. Anderson, A.G. Jariwalla, and M. Al Zaibak A comparison of oral metoprolol and propranolol in patients with chronic bronchitis J Int Med Res 8 1980 136 138 (Pubitemid 10148223)
6. 1-blocker (practolol) and exercise in patients with chronic obstructive lung disease Acta Med Scand 199 1976 61 64
7. J.W. Lammers, H.T. Folgering, and C.L. van Herwaarden Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease Br J Clin Pharmacol 20 1985 205 210 (Pubitemid 15228370)
8. L. Tivenius Effects of multiple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease Scand J Respir Dis 57 1976 190 196
9. A. Ranchod, G.R. Keeton, and S.R. Benatar The effect of beta-blockers on ventilatory function in chronic bronchitis S Afr Med J 61 1982 423 424 (Pubitemid 12158985)
10. W.R. Adam, E.J. Meagher, and C.E. Barter Labetalol, beta blockers, and acute deterioration of chronic airway obstruction Clin Exp Hypertens A 4 1982 1419 1428 (Pubitemid 12026853)
11. P. von Wichert Reversibility of bronchospasm in airway obstruction Am Heart J 104 1982 446 450 (Pubitemid 13157867)
12. W.H. Perks, S.S. Chatterjee, R.S. Croxson, and J.M. Cruickshank Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction Br J Clin Pharmacol 5 1978 101 106 (Pubitemid 8263485)
13. P. Dorow, H. Bethge, and U. Tonnesmann Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris Eur J Clin Pharmacol 31 1986 143 147 (Pubitemid 17014581)
14. I. Macquin-Mavier, F. Roudot-Thoraval, C. Clerici, C. George, and A. Harf Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction Br J Clin Pharmacol 26 1988 279 284
15. P. Dorow, A.M. Clauzel, P. Capone, R. Mayol, and M. Mathieu A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction J Cardiovasc Pharmacol 8 Suppl 4 1986 S102 S104
16. C.R. McGavin, and I.P. Williams The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction Br J Dis Chest 72 1978 327 332 (Pubitemid 9023010)
17. D.J. Sinclair Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis Br Med J 1 1979 168 (Pubitemid 9085261)
18. R.J. Butland, J.A. Pang, and D.M. Geddes Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema J Appl Physiol 54 1983 1368 1373 (Pubitemid 13098989)
19. R. Fogari, A. Zoppi, F. Tettamanti, L. Poletti, G. Rizzardi, and G. Fiocchi Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease Cardiovasc Drugs Ther 4 1990 1145 1149
20. P.E. Fenster, F.M. Hasan, T. Abraham, and J. Woolfenden Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease Clin Cardiol 6 1983 125 129 (Pubitemid 13162263)
21. H.J. van der Woude, J. Zaagsma, D.S. Postma, T.H. Winter, M. van Hulst, and R. Aalbers Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers Chest 127 2005 818 824 (Pubitemid 40775510)
22. M. Beil, and W.T. Ulmer Effects of a new cardioselective beta-adrenergic blocker (atenolol) on airway resistance in chronic obstructive disease Arzneimittelforschung 27 1977 419 422 (Pubitemid 8042016)
23. J. Wunderlich, H.N. Macha, H. Wudicke, and H. Huckauf Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease Effects and interaction after oral administration Chest 78 1980 714 720 (Pubitemid 11238668)
24. C.A. Sorbini, V. Grassi, C. Tantucci, T. Todisco, and M. Motolese Acute effects of oral metoprolol on ventilatory function in patients with chronic obstructive lung disease Acta Ther 8 1982 5 16
25. S. Salpeter, T. Ormiston, and E. Salpeter Cardioselective beta-blockers for chronic obstructive pulmonary disease Cochrane Database Syst Rev 4 2005 CD003566
26. R.J. Shelton, A.S. Rigby, J.G. Cleland, and A.L. Clark Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure Heart 92 2006 331 336
27. E. Kotlyar, A.M. Keogh, P.S. Macdonald, R.H. Arnold, D.J. McCaffrey, and A.R. Glanville Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma J Heart Lung Transplant 21 2002 1290 1295 (Pubitemid 35477743)
28. A. Camsari, S. Arikan, and C. Avan Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease Heart Vessels 18 2003 188 192 (Pubitemid 37258672)
29. J. Chen, M.J. Radford, Y. Wang, T.A. Marciniak, and H.M. Krumholz Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma J Am Coll Cardiol 37 2001 1950 1956 (Pubitemid 32499985)
30. K.K. Witte, A. Morice, J.G. Cleland, and A.L. Clark The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry J Card Fail 10 2004 149 154 (Pubitemid 38858076)
31. T.M. Ng, M.A. Munger, and W.L. Lombardi Chronically inhaled salmeterol improves pulmonary function in heart failure J Cardiovasc Pharmacol 40 2002 140 145 (Pubitemid 34705541)
32. N.G. Uren, S.W. Davies, S.L. Jordan, and D.P. Lipkin Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure Eur Heart J 14 1993 744 750 (Pubitemid 23198889)
33. The German and Austrian Xamoterol Study Group Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure Lancet 1 1988 489 493
34. The Xamoterol in Severe Heart Failure Study Group Xamoterol in severe heart failure Lancet 336 1990 1 6
35. D.R. Glover, C.G. Wathen, R.G. Murray, M.C. Petch, A.L. Muir, and W.A. Littler Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo Br Heart J 53 1985 208 215 (Pubitemid 15053142)
36. D.H. Au, E.M. Udris, V.S. Fan, J.R. Curtis, M.B. McDonell, and S.D. Fihn Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction Chest 123 2003 1964 1969 (Pubitemid 36706719)
37. D.H. Au, E.M. Udris, J.R. Curtis, M.B. McDonell, and S.D. Fihn Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists Am Heart J 148 2004 915 920
38. D.M. Sengstock, O. Obeidat, V. Pasnoori, P. Mehra, K.R. Sandberg, and P.A. McCullough Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study J Card Fail 8 2002 232 238
39. B. Mettauer, J.L. Rouleau, and J.H. Burgess Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure Am Heart J 109 1985 840 847 (Pubitemid 15118458)
40. P.D. Bourdillon, J.R. Dawson, R.A. Foale, A.D. Timmis, P.A. Poole-Wilson, and G.C. Sutton Salbutamol in treatment of heart failure Br Heart J 43 1980 206 210 (Pubitemid 10175916)
41. R. Slutsky Hemodynamic effects of inhaled terbutaline in congestive heart failure patients without lung disease: beneficial cardiotonic and vasodilator beta-agonist properties evaluated by ventricular catheterization and radionuclide angiography Am Heart J 101 1981 556 560 (Pubitemid 11120518)
42. F.X. Pamelia, M. Gheorghiade, and G.A. Beller Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial Am Heart J 106 1983 1369 1376 (Pubitemid 14214216)
43. R.M. Martin, N.R. Dunn, S.N. Freemantle, and R.D. Mann Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists Thorax 53 1998 558 562 (Pubitemid 28335515)
44. S.S. Coughlin, C. Metayer, and E.P. McCarthy Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy The Washington, DC, Dilated Cardiomyopathy Study Am J Epidemiol 142 1995 395 403
45. M.L. Bouvy, E.R. Heerdink, M.L. De Bruin, R.M. Herings, H.G. Leufkens, and A.W. Hoes Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure Arch Intern Med 160 2000 2477 2480
46. L. Staszewsky, M. Wong, S. Masson Valsartan Heart Failure Trial Investigators Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial J Card Fail 13 2007 797 804 (Pubitemid 350214524)
47. S.A. Hunt, W.T. Abraham, and M.H. Chin ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 46 2005 e1 e82
48. M. Jessup, W.T. Abraham, and D.E. Casey 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 53 2009 1343 1382
49. R.S. McNeill Effect of a beta-adrenergic-blocking agent, propranolol, on asthmatics Lancet 13 1964 1101 1102
50. J.M. Raine, M.G. Palazzo, J.H. Kerr, and P. Sleight Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane Br Med J (Clin Res Ed) 282 1981 548 549 (Pubitemid 11188775)
51. G. Zaid, and G.N. Beall Bronchial response to beta-adrenergic blockade N Engl J Med 275 1966 580 584
52. 1-selective beta-blockers J Clin Pharm Ther 28 2003 179 186 (Pubitemid 36783094)
53. W.H. Frishman Carvedilol N Engl J Med 339 1998 1759 1765
54. B.J. Clark Beta-adrenoceptor-blocking agents: are pharmacologic differences relevant? Am Heart J 104 1982 334 346 (Pubitemid 13157853)
55. A. Wellstein, D. Palm, and G.G. Belz Affinity and selectivity of beta-adrenoceptor antagonists in vitro J Cardiovasc Pharmacol 8 Suppl 11 1986 S36 S40
56. A. Veverka, D.S. Nuzum, and J.L. Jolly Nebivolol: a third-generation beta-adrenergic blocker Ann Pharmacother 40 2006 1353 1360
57. J. Wikstrand, B. Andersson, M.J. Kendall, H. Stanbrook, and M. Klibaner Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure J Cardiovasc Pharmacol 41 2003 151 157 (Pubitemid 36135237)
58. A.E. Tattersfield, D.J. Cragg, and R.J. Bacon Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man Br J Clin Pharmacol 18 1984 343 347 (Pubitemid 14033819)
59. P.J. Barnes Distribution of receptor targets in the lung Proc Am Thorac Soc 1 2004 345 351
60. L.S. On, P. Boonyongsunchai, S. Webb, L. Davies, P.M. Calverley, and R.W. Costello Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1320 1325 (Pubitemid 32506593)
61. N.M. Hawkins, M.R. MacDonald, and M.C. Petrie Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial Eur J Heart Fail 11 2009 684 690
62. S.R. Salpeter, T.M. Ormiston, E.E. Salpeter, P.J. Poole, and C.J. Cates Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis Respir Med 97 2003 1094 1101 (Pubitemid 37185112)
63. P. Dorow, S. Thalhofer, H. Bethge, G. Disselhoff, and G. Wagner Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study J Cardiovasc Pharmacol 16 Suppl 5 1990 S36 S44
64. P. Jones, S. Lareau, and D.A. Mahler Measuring the effects of COPD on the patient Respir Med 99 Suppl B 2005 S11 S18
65. P.W. Jones Health status measurement in chronic obstructive pulmonary disease Thorax 56 2001 880 887 (Pubitemid 32999838)
66. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
67. H. Krum, D. Ninio, and P. MacDonald Baseline predictors of tolerability to carvedilol in patients with chronic heart failure Heart 84 2000 615 619
68. A. Jabbour, P.S. Macdonald, and A.M. Keogh Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial J Am Coll Cardiol 55 2010 1780 1787
69. D.D. Sin, and F.A. McAlister The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure Am J Med 113 2002 650 656 (Pubitemid 36015801)
70. N.M. Hawkins, Z. Huang, K.S. Pieper VALIANT Investigators Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Eur J Heart Fail 11 2009 292 298
71. S.S. Gottlieb, R.J. McCarter, and R.A. Vogel Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction N Engl J Med 339 1998 489 497 (Pubitemid 28384881)
72. M.R. Bristow Beta-adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569 (Pubitemid 30080872)
73. M.R. Bristow, R. Ginsburg, and V. Umans Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure Circ Res 59 1986 297 309 (Pubitemid 17178124)
74. M. Packer Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure Circulation 82 Suppl 2 1990 I77 I88
75. 2- adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease Drugs 65 2005 1595 1610 (Pubitemid 41138983)
76. S.R. Salpeter, T.M. Ormiston, and E.E. Salpeter Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis Chest 125 2004 2309 2321 (Pubitemid 38796452)
77. P. Bremner, K. Woodman, and C. Burgess A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol Eur Respir J 6 1993 204 210 (Pubitemid 23074658)
78. T. Jartti, T. Kaila, K. Tahvanainen, T. Kuusela, T. Vanto, and I. Valimaki The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis Br J Clin Pharmacol 43 1997 421 428 (Pubitemid 27187482)
79. D.H. Au, R.N. Lemaitre, J.R. Curtis, N.L. Smith, and B.M. Psaty The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists Am J Respir Crit Care Med 161 2000 827 830 (Pubitemid 30171738)
80. D.H. Au, J.R. Curtis, N.R. Every, M.B. McDonell, and S.D. Fihn Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction Chest 121 2002 846 851 (Pubitemid 34251453)
81. 2 agonists in asthma Thorax 56 2001 506 507 (Pubitemid 32588526)
82. M. Cazzola, F. Imperatore, and A. Salzillo Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia Chest 114 1998 411 415 (Pubitemid 28387516)
83. J.P. Curtis, S.I. Sokol, and Y. Wang The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure J Am Coll Cardiol 42 2003 736 742 (Pubitemid 37000196)
84. D.M. Newnham, D.G. McDevitt, and B.J. Lipworth The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline Br J Clin Pharmacol 32 1991 630 632
85. D.M. Mannino, D. Thorn, A. Swensen, and F. Holguin Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Eur Respir J 32 2008 962 969
86. D.D. Sin, and S.F. Man Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease Circulation 107 2003 1514 1519 (Pubitemid 36378490)
87. C. Macie, K. Wooldrage, J. Manfreda, and N. Anthonisen Cardiovascular morbidity and the use of inhaled bronchodilators Int J Chron Obstruct Pulmon Dis 3 2008 163 169 (Pubitemid 351523729)
88. D.A. Grimes, and K.F. Schulz Compared to what? Finding controls for case-control studies Lancet 365 2005 1429 1433 (Pubitemid 40523738)
89. M. Packer Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists J Cardiovasc Pharmacol 14 Suppl 5 1989 S38 S43
90. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946 (Pubitemid 38807371)
91. B.J. Lipworth, D.M. Newnham, R.A. Clark, D.P. Dhillon, J.H. Winter, and D.G. McDevitt Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients Thorax 50 1995 54 61
92. J.A. Bennett, and A.E. Tattersfield Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects Thorax 52 1997 458 464 (Pubitemid 27278145)
93. R.M. Higgins, W.O. Cookson, D.J. Lane, S.M. John, G.L. McCarthy, and S.T. McCarthy Cardiac arrhythmias caused by nebulised beta-agonist therapy Lancet 2 1987 863 864
94. A.A. Fisher, M.W. Davis, and D.A. McGill Acute myocardial infarction associated with albuterol Ann Pharmacother 38 2004 2045 2049 (Pubitemid 40169373)
95. D.P. Moore, A. Weston, J.M. Hughes, C.M. Oakley, and J.G. Cleland Bronchial hyperresponsiveness in heart failure N Engl J Med 328 1993 1424 1425
96. R.E. Ruffin, G. Obminski, and M.T. Newhouse Aerosol salbutamol administration by IPPB: lowest effective dose Thorax 33 1978 689 693 (Pubitemid 9106421)
97. E.H. Walters, A. Cockroft, T. Griffiths, K. Rocchiccioli, and B.H. Davies Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels Thorax 36 1981 625 628 (Pubitemid 11054552)
98. F.P. Maesen, R. Costongs, J.J. Smeets, P.J. Brombacher, and P.G. Zweers The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations Chest 99 1991 1367 1373
99. C.A. Maak, J.A. Tabas, and D.E. McClintock Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med 40 2011 135 145
100. S. Thackray, J. Easthaugh, N. Freemantle, and J.G. Cleland The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failurea meta-regression analysis Eur J Heart Fail 4 2002 515 529 (Pubitemid 36564973)
101. A.J. Singer, C. Emerman, and D.M. Char Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease Ann Emerg Med 51 2008 25 34 (Pubitemid 350309450)
102. N. Freemantle, J. Cleland, P. Young, J. Mason, and J. Harrison Beta blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737 (Pubitemid 29290470)
103. M. Packer, A.J. Coats, M.B. Fowler Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658 (Pubitemid 32479962)
104. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
105. P.M. Calverley, J.A. Anderson, B. Celli TORCH Investigators Cardiovascular events in patients with COPD: TORCH study results Thorax 65 2010 719 725
106. B.A. Chowdhury, and P.G. Dal The FDA and safe use of long-acting beta-agonists in the treatment of asthma N Engl J Med 362 2010 1169 1171
107. D.P. Tashkin, B. Celli, S. Senn UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
108. S.P. Peters, S.J. Kunselman, N. Icitovic National Heart, Lung, and Blood Institute Asthma Clinical Research Network Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
109. S. Kesten, B. Celli, M. Decramer, I. Leimer, and D. Tashkin Tiotropium HandiHaler in the treatment of COPD: a safety review Int J Chron Obstruct Pulmon Dis 4 2009 397 409
110. T.M. Michele, S. Pinheiro, and S. Iyasu The safety of tiotropiumthe FDA's conclusions N Engl J Med 363 2010 1097 1099
111. C. Vogelmeier, B. Hederer, T. Glaab POET-COPD Investigators Tiotropium versus salmeterol for the prevention of COPD exacerbations N Engl J Med 364 2011 1093 1103